Independent · evidence-anchored·Reviewed by the GLPHelper Medical Team
EN·ES
glp·helper
Find a Provider →
glphelper.com/semaglutide/illinois/palatine
GLP-1 receptor agonistFDA-approved December 2017 (Ozempic) · June 2021 (Wegovy)Rx · Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)

Semaglutide® providers &
prescriptions in Palatine, IL

Verified Semaglutide providers in Palatine, IL. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
27
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Illinois
27 of 27 shown

Find a Semaglutide provider in Illinois.

Every entry is checked against the NPI registry and the Illinois medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Illinois city · /semaglutide/illinois/{city}
Arlington Heights
42.10°N
33 →
Schaumburg
42.03°N
24 →
Elgin
42.04°N
21 →
Gurnee
42.37°N
30 →
Waukegan
42.37°N
30 →
Oak Park
41.89°N
30 →
§ 03Getting Semaglutide in Palatine
27 providers · Palatine, IL

How to get Semaglutide in Palatine.

27 GLP-1 prescribers and 7 local resource types are on record for Palatine, plus 3 nearby towns in the directory.

Prescribers in Palatine
27 prescribers
27 GLP-1 prescribers in Palatine, most listed as Family Medicine (13), Internal Medicine (11) and Internal Medicine, Endocrinology, Diabetes & Metabolism (3). Any Illinois-licensed physician, nurse practitioner, or PA can prescribe Semaglutide, over video or in person. The nearest towns on record are Arlington Heights (33 providers), Schaumburg (24 providers) and Elgin (21 providers).
Around the prescription in Palatine
7 listed nearby
12 dietitians, 1 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Palatine.
Medicaid (weight loss)
Diabetes only
As of April 2026, Illinois Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Illinois’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.

Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]

In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]

At a glanceMultiple (brand-specific)
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017 (Ozempic) · June 2021 (Wegovy)
Approved use
Type 2 diabetes (Ozempic/Rybelsus) · chronic weight management (Wegovy)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy

Community health · CDC

Weight & metabolic health in Palatine

Palatine, Illinois has a population of 67,908 people. The adult obesity rate in Palatine is an age-adjusted estimate of 26.7%, 7.5 percentage points below the Illinois state rate of 34.2%. Diagnosed diabetes reaches 8.5% of adults in Palatine. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 18.9% of adults in Palatine.

of Palatine adults have obesity
26.7%
diagnosed diabetes
8.5%
no regular physical activity
18.9%

Age-adjusted estimates for Palatine, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossmale-specific GLP-1 side effects
§ 05Support around Semaglutide in Palatine
6 dietitians

The prescription is one part. Here is the rest, in Palatine.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Palatine, IL, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Gayle Booth, MS RD LDN CDE
RD
Registered dietitian
675 N North Ct
Call 847-701-8345NPI 1851618615
Haley Cecala
RD
Registered dietitian
800 Biesterfield Rd
Call 847-437-5500NPI 1053135236
Jainali Chanan, RD, LDN
RD
Registered dietitian · Obesity and Weight Management
1139 W Glencoe Rd
Call 847-654-7403NPI 1770264160
Ilysha Evans
RD
Registered dietitian
732 W Lakeside Dr
Call 847-909-0619NPI 1437895059
Emily Hehn, RDN, MBA
RD
Registered dietitian
2308 N Old Hicks Rd Unit 3
Call 224-306-8139NPI 1861325334
Elizabeth Keane, RD, LDN
RD
Registered dietitian
1185 N Sterling Ave Apt 204
Call 224-830-3250NPI 1619851482

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Justine Morrison, NTP
NUTRITIONIST
Nutritionist · Education
587 W Helen Rd
Call 312-919-8342NPI 1821932708
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.

STEP-1 randomized 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo; 86% of treated patients lost ≥5% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (Wegovy 2.4 mg)
−14.9%
STEP-1, 68 wk vs −2.4% placebo[2]
Patients losing ≥5% body weight
86%
STEP-1, 2.4 mg[2]
Major adverse cardiac events
−20%
SELECT, HR 0.80[3]
HbA1c reduction (T2D)
−1.4 to −1.8%
SUSTAIN program[4]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average semaglutide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
20 to 44%
mild
Most common; dose-dependent, usually eases after titration
Diarrhea
20 to 30%
mild
More frequent during dose escalation
Vomiting
16 to 24%
mild
Reduced by slower titration
Constipation
20 to 24%
mild
Abdominal pain
10%
moderate
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
1.6 to 2.6%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Wegovy (no insurance)
$1,300 to $1,400
per month
Brand-name retail average[6]
Cash, Ozempic (no insurance)
$950 to $1,150
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Wegovy is on-label but frequently requires PA and is denied
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $0 to $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Semaglutide providers in Illinois

NPI-verified Semaglutide (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Weight loss doctors in Illinois
Board-certified prescribers verified against the NPI registry.
Weight loss clinics in Illinois
Clinics running GLP-1 programs, telehealth & in-person.
Semaglutide in other states

Find NPI-verified Semaglutide (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Semaglutide in Alabama→Semaglutide in Alaska→Semaglutide in Arizona→Semaglutide in Arkansas→Semaglutide in California→Semaglutide in Colorado→Semaglutide in Connecticut→Semaglutide in Delaware→Semaglutide in Florida→Semaglutide in Georgia→Semaglutide in Hawaii→Semaglutide in Idaho→Semaglutide in Illinois→Semaglutide in Indiana→Semaglutide in Iowa→Semaglutide in Kansas→Semaglutide in Kentucky→Semaglutide in Louisiana→Semaglutide in Maine→Semaglutide in Maryland→Semaglutide in Massachusetts→Semaglutide in Michigan→Semaglutide in Minnesota→Semaglutide in Mississippi→Semaglutide in Missouri→Semaglutide in Montana→Semaglutide in Nebraska→Semaglutide in Nevada→Semaglutide in New Hampshire→Semaglutide in New Jersey→Semaglutide in New Mexico→Semaglutide in New York→Semaglutide in North Carolina→Semaglutide in North Dakota→Semaglutide in Ohio→Semaglutide in Oklahoma→Semaglutide in Oregon→Semaglutide in Pennsylvania→Semaglutide in Rhode Island→Semaglutide in South Carolina→Semaglutide in South Dakota→Semaglutide in Tennessee→Semaglutide in Texas→Semaglutide in Utah→Semaglutide in Vermont→Semaglutide in Virginia→Semaglutide in Washington→Semaglutide in West Virginia→Semaglutide in Wisconsin→Semaglutide in Wyoming→
Related GLP-1 research
hair shedding during weight loss
Why rapid loss can shed hair, and what helps it regrow.
the GLP-1 timeline to appetite suppression
When appetite changes show up, and when the weight curve usually follows.
do oral GLP-1 pills work
Pills and drops vs injections: what the evidence supports.
§ 09Frequently asked: Semaglutide in Illinois

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is the active molecule in all three Novo Nordisk products. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (2.4 mg/week). Insurers treat the brands as separate drugs.[1]